Position in FTRE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$294,987
-$245,196 QoQ
Shares Held
31,315
0.0% QoQ
Ownership
0.033%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in FTRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Cannell & Spears LLC holds $69,122,896 across 6 Biotechnology names. FTRE ranks #5 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
68,914 | $53,245,712 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
84,154 | $14,223,709 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,983 | $885,488 | |
| 4 | BNTX |
BioNTech SE
|
4,000 | $355,520 | |
| 5 | FTRE |
Fortrea Holdings Inc.
This page
|
31,315 | $294,987 | |
| 6 | ALEC |
Alector, Inc.
|
54,642 | $117,480 |
All Filings in FTRE
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $294,987 | 31,315 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $540,183 | 31,315 | Shares | Sole | 2026-02-17 | |
| 2025-06-30 | $54,409 | 11,014 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $126,447 | 16,748 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $312,350 | 16,748 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $458,500 | 22,925 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $540,064 | 23,139 | Shares | Sole | 2024-08-12 | |
| 2024-03-31 | $960,911 | 23,939 | Shares | Sole | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||